Adoptive immunotherapy of tumors with T cells specific for the cancer-testis antigen NY-ESO-1 has shown great promise in preclinical models and in early stage clinical trials. Tumor persistence or recurrence after NY-ESO-1-specific therapy occurs, however, and the mechanisms of recurrence remain poorly defined. In a murine xenograft model of NY-ESO-1 þ multiple myeloma, we observed tumor recurrence after adoptive transfer of CD8 þ T cells genetically redirected to the prototypic NY-ESO-1 157-165 peptide presented by HLA-A*02:01. Analysis of the myeloma cells that had escaped from T-cell control revealed intact expression of NY-ESO-1 and B2M, but selective, complete loss of HLA-A*02:01 expression from the cell surface. Loss of heterozygosity (LOH) in the major histocompatibility complex (MHC) involving the HLA-A locus was identified in the tumor cells, and further analysis revealed selective loss of the allele encoding HLA-A*02:01. Although LOH involving the MHC has not been described in myeloma patients with persistent or recurrent disease after immune therapies such as allogeneic hematopoietic cell transplantation (HCT), it has been described in patients with acute myelogenous leukemia who relapsed after allogeneic HCT. These results suggest that MHC loss should be evaluated in patients with myeloma and other cancers who relapse after adoptive NY-ESO-1-specific T-cell therapy.
INTRODUCTION
Adoptive transfer of T cells whose specificity has been genetically redirected to tumor-associated or -specific antigens is an increasingly feasible and effective therapeutic option for several cancers. [1] [2] [3] [4] [5] [6] [7] [8] [9] Redirection to tumor targets is achieved through transduction with vectors encoding T-cell receptors (TCRs)-specific for tumor peptides presented by major histocompatibility complex (MHC) molecules [10] [11] [12] [13] [14] [15] -or chimeric antigen receptors. 16, 17 This genetic modification can overcome central and peripheral tolerance, and enable the production of autologous products containing large number of highly potent tumor-reactive T cells from most patients, even those who harbor few, if any, native tumor-reactive T cells in their blood. 8, [10] [11] [12] [13] [14] [15] [18] [19] [20] [21] Multiple myeloma (MM) is a suitable malignancy in which to evaluate adoptive therapy with T cells redirected toward cancertestis (C-T) antigens such as NY-ESO-1. Evidence demonstrates that NY-ESO-1 and other C-T antigens are often expressed in the tumor cells of patients with advanced MM. [22] [23] [24] [25] [26] Primary MM cells from most patients also demonstrate preserved expression of MHC class I molecules, making myeloma particularly suitable for targeting with myeloma-reactive TCRs. [27] [28] [29] These observations have prompted both preclinical studies 21 and clinical trials 3, 30 of adoptive therapy for myeloma with autologous T cells transduced with NY-ESO-1-specific TCRs or chimeric antigen receptors. Most of these studies targeted the NY-ESO-1 157-165 peptide presented by HLA-A*02:01. An affinity-enhanced variant of the 1G4 TCR specific for NY-ESO-1 157-165 /HLA-A*02:01 demonstrated significant activity in preclinical studies, 31 and a phase I/II clinical trial in patients with advanced melanoma and synovial sarcoma confirmed the safety and efficacy of adoptive therapy with autologous T cells transduced with this TCR. 2 Alternative strategies for targeting the NY-ESO-1 157-165 /HLA-A*02:01 complex are being explored. A bispecific T cell-engaging molecule that couples a high affinity, soluble variant of the 1G4 TCR to a single chain, human CD3-specific antibody variable fragment demonstrated in vitro activity against NY-ESO-1 þ /HLA-A*02:01 þ tumor cell lines, but had limited in vivo efficacy in a subcutaneous xenograft model of NY-ESO-1 þ bladder carcinoma. 32 A CAR recognizing the NY-ESO-1 157-165 /HLA-A*02:01 peptide complex has also been constructed, and T cells from healthy donors that expressed this CAR showed significant in vivo antitumor activity in a murine xenograft model of human MM. 21 Despite encouraging results from studies evaluating NY-ESO-1 157-165 /HLA-A*02:01-specific therapy, persistence or recurrence of disease has consistently been observed in a subset of subjects. Potential mechanisms of tumor escape include: poor persistence of adoptively transferred T cells; loss of expression of NY-ESO-1, MHC class I, or both in myeloma cells; inability of T cells to penetrate into the tumor microenvironment; and post-infusion inhibition of T-cell function by suppressor cells or cytokines in the tumor microenvironment, among others. We observed recurrence of myeloma in a murine xenograft model after adoptive therapy with NY-ESO-1 157-165 /HLA-A*02:01-specific T cells, and describe our evaluation of the mechanism of tumor escape in this model.
RESULTS
Transduction of MM patient lymphocytes with 1G4 a95:LY TCR T cells from G-CSF-mobilized leukapheresis products from HLA-A*02:01 þ MM patients were transduced with a retrovirus encoding the affinity-enhanced a95:LY variant of the 1G4 NY-ESO-1 157-165 -specific, HLA-A*02:01-restricted TCR. 31 1 TCR-transduced cells were identified using a NY-ESO-1 157-165 /HLA-A*02:01-specific tetramer ( Figure 1a ). Flow-sorted CD8 þ tetramer þ and CD8 þ tetramer À cells were tested for recognition of target cells that expressed the NY-ESO-1 157-165 peptide, HLA-A*02:01, both or neither. Only CD8 þ tetramer þ cells demonstrated significant cytotoxicity against target cells that expressed both NY-ESO-1 157-165 peptide and HLA-A*02:01 ( Figure 1b ).
Adoptive transfer of NY-ESO-1-specific T cells improves survival of myeloma-bearing mice
The in vivo activity of sorted CD8 þ tetramer þ 1G4 a95:LY TCRtransduced T cells (termed TCR-transduced T cells) derived from a HLA-A*02:01 þ MM patient was assessed in an immune-deficient mouse xenograft model of disseminated human MM (Figure 2a ). Eighteen mice were sub-lethally irradiated 1 day prior to tail-vein injection of luciferase-transduced U266 (termed U266/Luc) human MM cells, which uniformly express CD138, NY-ESO-1, and HLA-A2 (Figures 3a and b ). Subsequently, mice were divided into three cohorts to receive two daily injections of phosphate-buffered saline (PBS), 1 Â 10 7 sham-transduced T cells or 1 Â 10 7 TCRtransduced T cells.
Mice in the PBS cohort developed detectable MM within 2 weeks and thereafter progressed steadily ( Figure 2b ). All such mice met criteria for euthanasia by week 9. Mice receiving shamtransduced T cells exhibited slower development of myeloma compared with those that received PBS ( Figure 2b , and Supplementary Figure 1 ), but nonetheless uniformly developed progressive myeloma and met criteria for euthanasia by day þ 127 (18 weeks). Of the six mice in the TCR-transduced cohort, four (mice 1-4) had no evidence of MM by either bioluminescence or necropsy evaluation at the end of study (day þ 128). Two mice in this group (mice 5 and 6), however, had a low burden of MM detected by bioluminescence at the time of their sacrifice on day þ 128 (Figures 2b and c) . Flow cytometric examination of tissues harvested from mice of the PBS and sham-transduced cohorts demonstrated evidence of myeloma cells in both bone marrow and blood, but no significant engraftment in either liver or spleen (data not shown). There was no evidence of U266/Luc cells in mice 1-4 of the TCR-transduced cohort. U266/Luc cells were present in the bone marrow of mice 5 and 6, the two mice that developed myeloma by bioluminescence ( Figure 3a) .
Kaplan-Meier analysis demonstrated significant improvement of overall survival in the groups that received T cells, with the best survival noted in the cohort that received TCR-transduced T cells (Log-rank test Po0.001; Figure 2d ). One of the mice that received TCR-transduced T cells died unexpectedly on day þ 127, but no evidence of MM was detected by either bioluminescence or postmortem exam. LOH in the MHC underlying selective loss of HLA-A*02:01 expression To evaluate whether selective loss of HLA-A2 expression in the myeloma xenografts resistant to NY-ESO-1-specific T cells was 10: associated with changes in the genomic locus containing the HLA-A*02:01 allele, loss of heterozygosity (LOH) analysis was performed. The genotypes of the parental U266 and U266/Luc cells, and the human CD138 þ cells recovered from mice in the PBS, sham-transduced, and TCR-transduced cohorts were determined at six short tandem repeat (STR) loci spanning the MHC in the chromosome 6p21.3 region and two loci on chromosome 15 (Figure 3c ). The parental U266 and U266/Luc cells, and the myeloma cells recovered from the mice that received either PBS or sham-transduced T cells, have identical genotypes at these six loci, and are heterozygous at five of the six STR loci on chromosome 6p21.3 and one of two loci on chromosome 15. Bone marrow cells from mice without evidence of disease had minimal to no signal (mouse 1 on Figure 3c ). In contrast, myeloma cells isolated from mice 5 and 6 of the TCRtransduced cohort had evidence for LOH at several STR loci on chromosome 6p21.3, involving the MHC and the HLA-A locus, but not at the loci on chromosome 15 (Figure 3c ). LOH was observed at three loci in myeloma cells from mouse 5 and at five in mouse 6, suggesting that the genomic events occurring in the myeloma cells from the two mice were not identical. Analysis of the STR fragment sizes at the affected loci, however, suggested involvement of the same HLA-A allele in the two cases (Figure 3c ). To confirm this conclusion, HLA-A typing by PCR was performed.
Escape from NY-ESO-1-specific T-cell therapy via selective loss of HLA-A2 expression
Although the parental U266 and U266/Luc cells were typed as HLA-A*02/HLA-A*03, the myeloma cells recovered from the two mice were typed as HLA-A*03, demonstrating that the LOH events involved the HLA-A*02 allele in both cases (Figure 3d ).
DISCUSSION
Current techniques for redirecting the antigenic specificity of T cells to tumor-associated or -specific antigens via TCR or CAR gene transfer allow for reliable generation of T-cell products with potent antitumor activity. Using a vector that encodes an affinityenhanced TCR specific for NY-ESO-1, we redirected CD8 þ T cells from MM patients to recognize the NY-ESO-1 157-165 peptide presented by HLA-A*02:01. TCR-transduced cells were specifically cytolytic against NY-ESO-1 þ HLA-A*02:01 þ MM cells, and adoptive transfer of TCR-transduced cells was protective against an otherwise lethal challenge of MM cells in four of six mice. Two mice developed MM despite adoptive therapy with TCR-transduced T cells, and analysis of the tumor cells in these mice revealed selective loss of expression of HLA-A*02:01, associated with LOH in the MHC, as the likely mechanism of immune escape. An intriguing observation is the lag in disease development in mice that received sham-transduced T cells. We hypothesize that this lag was due to weak alloreactivity of the polyclonal CD8 þ sham-transduced T cells against U266/Luc. Other studies of adoptive T-cell therapy targeting NY-ESO-1 have likewise demonstrated potent antitumor activity but occasional therapeutic failures. 2, 3, 21, 30 A recent preclinical study of adoptive therapy with T cells expressing a CAR specific for the NY-ESO-1 157-165 /HLA-A*02:01 complex showed in vivo activity against the human U266 MM line, but resistance was observed in some animals. 21 The mechanism underlying resistance in this study was not investigated. Adoptive therapy with autologous T cells transduced with the a95:LY variant of the 1G4 TCR used in our study was evaluated in a clinical trial in melanoma and sarcoma patients. Clear antitumor activity was observed in some but not all patients. 2 An ongoing trial of a very similar approach in patients with advanced MM has similarly shown objective clinical responses in many patients, but lack of response in others. 3, 30 Given abundant evidence that in vivo persistence of adoptively transferred T cells correlates with response, much attention has been focused on the lack of T-cell persistence as the main mechanism for treatment failure. However, other potential mechanisms such as antigen loss, inability of T cells to migrate within the tumor microenvironment, and post-infusion inhibition of T-cell function are also possible. For example, antigen loss has recently been described in a patient with acute lymphocytic leukemia who received autologous CD19-CAR-transduced T cells. 18 MHC class I loss, as demonstrated in our study, is a potential mechanism by which tumors can escape adoptive therapy with CD8 þ T cells expressing tumor-reactive TCRs. Loss of MHC class I expression has been described extensively in solid tumors (reviewed in Garcia-Lora et al. 33 ) and has been associated with LOH in patients with acute leukemia or high-risk myelodysplastic syndrome who relapsed after haploidentical HCT. 34, 35 In the latter setting, it is likely that mitotic recombination in the tumor cells led to acquired uniparental disomy for the short arm of chromosome 6 and resultant loss of the non-shared MHC haplotype, thereby allowing the tumor cells to escape from recognition by donor T cells specific for MHC molecules encoded on that haplotype. Published reports on the outcome of haploidentical transplantation in patients with MM are limited, [36] [37] [38] however, and it is unknown if the same phenomenon can occur in MM cells after haploidentical transplantation. More generally, the extent to which MHC loss can contribute to recurrence of MM after T cell-based immunotherapy-such as donor lymphocyte infusion after allogeneic HCT [39] [40] [41] [42] [43] [44] -is also unknown. The observation in our study of escape from NY-ESO-1-directed adoptive T-cell therapy via specific loss of the MHC allele recognized by the TCR-transduced cells, however, suggests that immune escape due to MHC loss could also occur in the clinical setting. Although our study is based on a genetically unstable human MM cell line, relapsed MM patients exhibit genetic instability and clonal evolution. Given that adoptive T-cell therapy targeting NY-ESO-1 is currently being evaluated in clinical trials, 3 close monitoring for MHC class I loss and related mechanisms of immune escape is warranted.
MATERIALS AND METHODS

Cell culture
The MM cell lines U266 (ATCC, Manassas, VA, USA) and UM-9 (kind gift from Drs Tuna Mutis and Henk Lokhorst, University of Utrecht, The Netherlands) were cultured in complete medium comprising RPMI-HEPES, 1% penicillin-streptomycin, 1% L-glutamine and 20% FBS. T2 cells were cultured in complete medium with 10% FBS. U266 was transduced with a retrovirus (kind gift from Dr Elizabeth Budde, FHCRC), comprising a MMLV backbone with firefly luciferase, a neomycin resistance gene, and THY1.1 as a reporter. The retrovirus was produced in the packaging cell line Phoenix G. Transduced cells were subsequently selected in 800 mg ml À 1 geneticin (Sigma-Aldrich, St. Louis, MO, USA) to produce the U266-Luc cell line. All PBMC and T cells were cultured in RPMI 1640 medium supplemented with 1% penicillin-streptomycin, 10 mM L-glutamine, 50 mM 2-mercaptoethanol (Sigma-Aldrich), and 10% heat-inactivated human serum. T cells were expanded with 30 ng ml À 1 of anti-CD3 antibody (Centocor Ortho Biotech, Horsham, PA, USA) and 50 IU ml À 1 of interleukin-2 (Novartis, Basel, Switzerland) as previously described 45 for 13-15 days prior to their use in functional assays.
Generation and functional evaluation of NY-ESO-1 157-165 /HLA-A*02:01-specific T cells MM patients undergoing autologous stem cell collection via leukapheresis were enrolled on an IRB-approved protocol to provide up to 10 ml of leukapheresis product after the targeted CD34 þ cell count was collected. The products were washed with PBS/EDTA, counted, and cryopreserved. HLA-A typing of patient samples was performed using the HLA-A locus Allset Gold SSP Low Resolution (Invitrogen, Carlsbad, CA, USA). Mononuclear cells from leukapheresis products were transduced with a retrovirus containing the MSGV1 backbone and encoding the aand b-chains of a variant of the 1G4 TCR specific for NY-ESO-1 157-165 / HLA-A*02:01 with dual amino-acid substitutions at positions 95-96 in the a-chain (a95:LY), packaged in the Phoenix Ampho cell line. 31, 46 After activation with anti-CD3 antibody (Centocor Ortho) at 300 ng ml À 1 for 24 h, the cells were spinoculated in the presence of protamine (Sigma-Aldrich) and interleukin-2 on each of two subsequent days. Shamtransduced T cells were obtained in an analogous fashion, but in the absence of retroviral vector. Cytotoxicity was determined by 51 Cr release assay, as previously described. 46 Human myeloma xenografts Eighteen NOD/SCID/interleukin-2 Rg À / À (NSG) mice were irradiated with 250 cGy from a 137 Cs source (JL Shepherd Mark I) to allow for reproducible xenografting. 47 One day after irradiation, three cohorts of six mice each received 5 Â 10 6 U266/Luc cells via tail-vein injection. 
Flow cytometry
Transduced cells were evaluated for expression of the 1G4/a95:LY TCR using an APC-labeled NY-ESO-1 157-165 /HLA-A*02:01 tetramer (Immune Monitoring Facility, FHCRC) and anti-CD8-FITC (BD Biosciences). CD8 þ / tetramer þ population was isolated by fluorescence-activated cell sorting (FACS). Engraftment of U266/Luc in the blood, bone marrow, and selected organs of xenografted mice was assessed using anti-CD138-APC, anti-HLA-A2-FITC and -APC and anti-human MHC class I-FITC antibodies (BD Biosciences).
LOH analysis
Integrity of the MHC in genomic DNA from MM cells recovered from the xenografted mice in all treatment groups was assessed by LOH analysis with previously defined STR markers mapping to chromosomes 6 and 15. 48 Multiplex PCR amplification was performed using Multiplex PCR kit (Qiagen, Hilden, Germany). Each 20 ml reaction contained 1.2 ml of genomic DNA, 2 ml of Primer Mix (final concentration 5 mM each primer), 10 ml of 2 Â Multiplex master mix and 2 ml of 5 Â Q solution. Tagged primer combinations included: mix 1: D6S105 (6-FAM); D6S276 (TET); mix 2: D6S291 (6-FAM)-D6S273 (TET); mix 3: D15S209 (6-FAM) D6S311 (6-FAM); mix 4: D6S126 (6-FAM) D6S275 (6-FAM). The D6S1618 (TET) marker was evaluated alone. Amplification of STR loci was performed on the Mastercycler ProS (Eppendorf, Hamburg, Germany) using a thermal cycling profile of 95 1C for 15 min; 40 cycles of 94 1C for 30 s, 55 1C for 40 s, 72 1C for 45 s; and 72 1C for 10 min. Aliquots of each PCR reaction were diluted 1:100 and the products were separated on an ABI-3730xl Genetic Analyzer and quantitated using GeneMapper v4 software.
Statistical analysis
Survival differences were analyzed using the Kaplan-Meier method with correction for multiple comparisons. Serial bioluminescence levels in the three groups of xenografted mice were analyzed by one-way analysis of variance. A P-value of o0.05 was considered significant, and a Bonferroni adjustment was applied to correct for multiple comparisons.
